secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001625297-25-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal
--------------------------------------------------------------------------------

- Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.
- Ciaffoni gets base salary $1,050,000, bonus target 100% of salary, max 200%; on-hire PSUs worth 12x salary (up to 1.575M shares) and RSUs 4x salary (up to 525K shares).
- Board reduced to 7 directors at 2025 AGM; Peter Bains and Jo LeCouilliard not standing for re-election; Robert Schriesheim resigned effective March 2.
- Amended relationship with Oaktree: board to be 8 after search for one new independent director by July 1; Daniel Ninivaggi chairs Nomination Committee.
- Barbara Ryan to succeed Jo LeCouilliard as Chair of Compensation Committee after the 2025 AGM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/0001625297-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000021/indv-20250302.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer